Related Experiment Video
Updated: Feb 6, 2026

Intravitreal Injections in the Ovine Eye
Published on: July 5, 2022
Safety of 5914 intravitreal ziv-aflibercept injections
Sumit Randhir Singh1, Michael W Stewart2, Goura Chattannavar1
1Smt. Kanuri Santhamma Centre for Vitreo-Retinal Diseases, L V Prasad Eye Institute, Hyderabad, India.
Purpose:
To analyse the pooled safety data of intravitreal ziv-aflibercept (IVZ) therapy for various retinal conditions.
Methods:
This was a retrospective, observational study which included patients from 14 participating centres who received IVZ. The medical records of patients who received IVZ from March 2015 through October 2017 were evaluated. Patient demographics and ocular details were compiled. Ocular and systemic adverse events that occurred within 1 month of IVZ injections were recorded and defined as either procedure-related or drug-related.
Results:
A total of 1704 eyes of 1562 patients received 5914 IVZ injections (mean±SD: 3.73±3.94) during a period of 2.5 years. The age of patients was 60.6±12.8 years (mean±SD) and included diverse chorioretinal pathologies. Both ocular (one case of endophthalmitis, three cases of intraocular inflammation, and one case each of conjunctival thinning/necrosis and scleral nodule) and systemic adverse events (two cases of myocardial infarction, one case of stroke and two deaths) were infrequent.
Conclusion:
This constitutes the largest pooled safety report on IVZ use and includes patients from 14 centres distributed across the globe. It shows that IVZ has an acceptable ocular and systemic safety profile with incidences of adverse events similar to those of other vascular endothelial growth factor inhibitory drugs. The analysis supports the continued use of IVZ in various retinal disorders.
Related Concept Videos
Survey Safety
Household Wiring And Electrical Safety
Gas Chromatography: Sample Injection Systems
Two primary injection methods are used...
Nonlinear Pharmacokinetics: Drug Elimination for IV Bolus Injection
Following the administration of a single intravenous (IV) bolus injection, we can determine the concentration of the drug in the plasma at any given time. This calculation is achieved using a specific equation that integrates the values of Vmax and KM.
We can also...
Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Bystander Effect

